Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing
Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…
AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.
UnitedHealthcare to nix nearly two thirds of pediatric prior auths
fiercehealthcare - UnitedHealthcare is set to eliminate close to two-thirds of pediatric prior authorization requirements by the end of the year.
AI Summary: UnitedHealthcare announced a major rollback of pediatric prior authorization requirements, eliminating roughly two‑thirds of those rules to reduce administrative burden and speed care for children. The move aims to ease clinician frustration and patient delays, while insurers and providers brace for workflow and cost‑management implications.
Care navigation startup Garner Health banks $100M series E at $2.74B valuation
fiercehealthcare - The startup plans to use the capital to expand its provider quality platform, scale AI-powered product innovation and expand access.
AI Summary: Care navigation platform Garner Health closed a $100 million financing round to scale patient navigation and referrals to high‑performing clinicians, drawing strategic participation including Kaiser. The funding fuels expansion of tech‑enabled matchmaking between patients and clinicians while investors chase better outcomes and lower downstream costs.
Walmart, Teladoc Team Up to Expand Access to Virtual Care
Marissa Plescia / medcitynews - Through a new partnership, Teladoc Health’s virtual services are now available on Walmart’s Better Care Services platform.The post Walmart, Teladoc Team Up to Expand Access to Virtual Care appeared first on MedCity News.
AI Summary: Walmart has integrated Teladoc’s virtual care services into its digital health platform, rolling out expanded telemedicine access through its channels. The partnership merges Teladoc’s clinical offerings with Walmart’s scale to lower barriers to care, steer routine visits online, and extend convenient virtual options to price‑sensitive consumers — because waiting rooms are so last century.
CMS Finalizes Rule to Simplify Payer-Provider Disputes Under No Surprises Act
Katie Adams / medcitynews - CMS finalized a new rule aimed at streamlining the No Surprises Act’s overwhelmed arbitration system. Provider groups largely welcomed the reforms — though some industry leaders said additional changes are still needed to address alleged misuse and improv…
AI Summary: The Centers for Medicare & Medicaid Services finalized a rule to simplify payer‑provider disputes under the No Surprises Act, updating the dispute resolution process and implementing a payer registry and portal changes. The aim is to reduce administrative friction, speed dispute handling, and make billing arbitration less of an endurance sport for providers and insurers.
CVS sues to challenge new Tennessee PBM-pharmacy breakup law
Rebecca Pifer Parduhn / healthcaredive - The law, which would prohibit PBM conglomerates from owning or operating pharmacies, illegally boots out-of-state companies from Tennessee’s pharmacy market, CVS argued in suit filed Friday.
AI Summary: CVS Health has filed suit challenging Tennessee's new law that bars pharmacy benefit managers from owning pharmacies, arguing the measure unlawfully disrupts established business models and harms patient access. The company seeks to block enforcement while the legal fight plays out, setting up a clash between state regulators and a major healthcare middleman.
Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth
fiercehealthcare - Oura, the smart ring maker, filed confidentially for an initial public offering after it reached an $11 billion valuation last year.
AI Summary: Ōura has quietly filed confidential paperwork to go public, leveraging surging consumer demand for its smart rings and an aggressive pivot into healthcare data and services. The company is pitching its wearable as a clinical-grade monitoring platform to insurers and providers, aiming to monetize sleep, activity and biometrics while navigating privacy and regulatory scrutiny.
CommonSpirit $3.4B in the red amid billing contract exit, operational woes
Rebecca Pifer Parduhn / healthcaredive - The Catholic nonprofit giant’s expenses well outstripped revenue in the most recent financial quarter. Though the outcome was mostly due to one-time items, CommonSpirit also continues to struggle with boosting core operations.
AI Summary: CommonSpirit reported a multi‑billion‑dollar shortfall tied to operational challenges and the exit from a major billing contract, recording a substantial loss and a weakened operating margin in the quarter. The results have spurred leadership to reassess financial strategy and cost controls as the system navigates recovery and operational stabilization.
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
Lei Lei Wu / endpoints - The FDA has approved the TROP2-directed antibody-drug conjugate Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor Gilead. The approval marks Datroway’s third, after ...
AI Summary: Daiichi Sankyo and AstraZeneca’s breast cancer therapy Datroway has cleared key regulatory hurdles, winning FDA approval and earning backing from European regulators. The approvals validate pivotal trial results and pave the way for clinical adoption in the indicated patient population, prompting clinicians to prepare for integration into treatment pathways and health systems to weigh formulary and access decisions.
- Clinicians weigh Datroway’s role in TNBC care (3)
- FDA win and market stakes for Datroway (3)
- All Other Stories
Clinicians weigh Datroway’s role in TNBC care
FDA win and market stakes for Datroway
All Other Stories
Nearly 10% of surgeons are leaving the profession within 8 years
medicalxpress - Surgeons are an integral part of the health care system, supplying critical and urgent care in nearly every field of medicine. But surgeons are already in short supply, with the gap between the number needed and the number working expected to get worse.
AI Summary: A recent report reveals that roughly one in ten surgeons leave clinical practice within eight years of starting, spotlighting a troubling attrition rate that threatens surgical capacity. The findings point to burnout, workload and systemic pressures as likely drivers and underscore the need for retention strategies, training support and policy changes to stabilize the surgical workforce.
Providence shuts down most insurance businesses for 2027
Rebecca Pifer Parduhn / healthcaredive - The nonprofit giant has offered health insurance for decades. But recent challenges, including higher costs and regulatory changes, have placed Providence in an untenable position, according to the integrated system’s CEO.
AI Summary: Providence announced plans to shut down or substantially scale back its insurance businesses by 2027, citing unsustainable operations and strategic misalignment. The health system will refocus on core care delivery, a move that will ripple through regional insurance markets, affect covered members, and require careful transition planning to maintain access.
BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test
Reynald Castaneda / endpoints - BioMarin’s enzyme replacement therapy for a rare genetic disorder called ENPP1 deficiency delivered mixed results in a late-stage study. Patients with the condition don't produce enough of the ENPP1 enzyme, which generates plasma inorganic pyrophosphate .…
AI Summary: BioMarin reported a Phase 3 trial that failed to show clinical benefit for a rare‑disease therapy, undermining prior optimism and clouding the drug’s development pathway. The mixed late‑stage results force a strategic reassessment, cooling investor expectations and leaving researchers and patients waiting for next steps or alternative approaches.
Quorum Health strikes deal to become nonprofit
Kelly Gooch / beckershospitalreview - Quorum Health, a for-profit system headquartered in Brentwood, Tenn., has signed a definitive agreement with nonprofit health system Healthside Partners to transition Quorum into a nonprofit organization spanning 11 hospitals across nine states. With the …
AI Summary: Quorum Health agreed to become a nonprofit through a transaction with Healthside Partners to avert insolvency, rescue struggling hospitals, and stabilize finances. Executives frame the conversion as a survival strategy to maintain care access, restructure operations, and shift priorities from profitability to community health amid mounting fiscal pressure.
GHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investor
Reynald Castaneda / endpoints - European healthcare investor GHO Capital and asset management firm CBC Group are set to join forces, with the new entity to manage over $21 billion. In a Wednesday release, they said ...
AI Summary: GHO Capital and CBC Group have agreed to combine their healthcare investment platforms to create roughly a $21 billion specialist investor focused on health assets. The tie-up consolidates capital and deal teams to chase larger transactions across care delivery, pharma and tech—because apparently healthcare needed a bigger private-equity behemoth.
Toronto Rock take NLL Cup with win over Halifax Thunderbirds
Denio Lourenco / citynews - Owen Hiltz and Chris Boushy each had three goals and an assist, Mark Matthews had a goal and three assists, and Nick Rose made 34 saves as the Toronto Rock defeated the Halifax Thunderbirds 12-7 to win the National Lacrosse League championship on Sunday a…
AI Summary: A clinical study shows that delivering just two ablative radiotherapy sessions over eight days achieves effective control of localized prostate cancer without adding side effects, offering a dramatically shorter, patient‑friendly regimen. If adopted more widely, the approach could reduce treatment burden, clinic visits and health‑system costs while maintaining cancer control.
Nourish Secures $100M for Metabolic Health Clinic
Marissa Plescia / medcitynews - Nourish’s Series C round was led by Menlo Ventures, with participation from Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak and Operator Partners.The post Nourish Secures $10…
AI Summary: Nourish secured a $100 million funding round to expand its virtual metabolic-health and nutrition care model, doubling down on physician integration and broader clinical rollout. The company plans to scale tele-nutrition services and deepen provider partnerships to treat metabolic disease at home, aiming to convert weight and metabolic management into reimbursable medical care.
CMS finalizes major changes to ACA exchanges, including greater access to catastrophic plans
Rebecca Pifer Parduhn / healthcaredive - The Trump administration continues to open the doors to the cheap, high-deductible coverage, to the worry of insurance experts and stakeholders in the healthcare industry.
AI Summary: In a sweeping final rule, CMS loosened constraints on ACA marketplace offerings to broaden consumer choice — including expanded access to catastrophic plans and relaxed limits on non-standard plan designs. The changes aim to reshape the 2027 exchanges, boost affordability and enrollment flexibility, and hand insurers new product wiggle room while regulators expect close scrutiny.
- CMS final rule loosens plan design, expands catastrophic access (4)
- Insurers exit and consumers pivot to cheaper alternatives (3)
- Rising costs and shrinking ACA enrollment threaten markets (4)
CMS final rule loosens plan design, expands catastrophic access
Insurers exit and consumers pivot to cheaper alternatives
Rising costs and shrinking ACA enrollment threaten markets
BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
Ayisha Sharma / endpoints - BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label. The FDA greenlit ...
AI Summary: BeOne Medicines secured FDA approval for a next-generation BCL2 inhibitor, positioning the drug as a direct challenge to AbbVie/Roche’s Venclexta franchise. The move reshuffles competitive dynamics in hematology, potentially offering clinicians an alternative and setting the stage for market share battles and payer negotiations. Expect aggressive positioning and head-to-head data requests.
Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape
oncodaily - Bristol Myers Squibb (NYSE: BMY) and Jiangsu Hengrui Pharma (600276.SH; 01276.HK) on Tuesday unveiled one of the largest cross-border biopharma collaborations of the year: a global strategic alliance encompassing 13 […]
AI Summary: Bristol Myers Squibb and Hengrui Pharma announced a sweeping strategic alliance covering multiple oncology assets, with potential payments and milestones that could reach roughly $15.2 billion. The deal bundles discovery, development and commercialization rights, reshaping China‑out‑licensing dynamics and signaling continued consolidation and collaboration in global cancer drug development.
CMS launches initiative to speed electronic prior authorization adoption
Emily Olsen / healthcaredive - The effort, part of the agency’s ambitious Health Tech Ecosystem, aims to accelerate the industry’s progress before requirements on electronic prior authorization go into effect next year.
AI Summary: CMS launched a national initiative to accelerate adoption of electronic prior authorization, recruiting major health‑IT vendors and health systems to pilot interoperable digital workflows. The program aims to cut paperwork and speed care decisions by automating approvals, though providers warn integration challenges and real‑world impact will take time to materialize.
- AI and automation firms reshaping prior authorization workflows (4)
- CMS' national push to accelerate electronic prior authorization (3)
- Policy fights, insurer delays and patient impact of prior auth (4)
- All Other Stories